Serum sCD25/ferritin ratio combined with MCP-1 is a valid predictor for identifying LAHS with HLH as the first manifestation
- PMID: 37093345
- PMCID: PMC11798138
- DOI: 10.1007/s00432-023-04781-4
Serum sCD25/ferritin ratio combined with MCP-1 is a valid predictor for identifying LAHS with HLH as the first manifestation
Abstract
Purpose: Lymphoma-associated haemophagocytic syndrome (LAHS) is a group of malignant diseases with rapid progression and a high mortality rate. Our study aimed to discover the significance of serum sCD25/ferritin ratio as well as cytokines in assisting the diagnosis of LAHS.
Methods: We retrospectively analyzed the clinical data of 82 patients with LAHS with hemophagocytic lymphohistiocytosis (HLH) as the first manifestation and divided them into B-LAHS group and T/NK-LAHS group according to lymphoma pathological diagnosis for comparison. And patients with LAHS were divided into responding group, non-responding group according to the assessment of efficacy after receiving DEP/L-DEP induction therapy for 2 weeks to compare possible valuable indicators.
Results: Serum sCD25/ferritin ratio and MCP-1 levels were significantly different between B-LAHS and T/NK-LAHS groups (P = 0.001, P = 0.022). An sCD25/ferritin ratio > 7.8 tended to suggest a diagnosis of B-LAHS (AUC = 0.71, 95% CI: 0.596-0.823), and the sCD25/ferritin ratio had better predictive value when combined with MCP-1 (AUC = 0.81, 95% CI: 0.699-0.922). The sCD25/ferritin ratio was also significantly different between the two groups responding or not responding to induction therapy (P = 0.002), yielding an optimal cutoff value of 11.48. An sCD25/ferritin ratio > 11.48 tended to suggest that the patient's LAHS was responsive to induction therapy.
Conclusion: Our study reveals that serum sCD25/ferritin ratio combined with MCP-1 is a valid predictor for identifying LAHS with HLH as the first manifestation and may assist in predicting whether the lymphoma is of B-cell or T/NK-cell origin. The sCD25/ferritin ratio can also be used to predict the early response of LAHS after induction therapy.
Keywords: Cytokine; Diagnosis; Ferritin; Hemophagocytic lymphohistiocytosis; Non-Hodgkin lymphoma; sCD25.
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Conflict of interest statement
The authors have no relevant financial or non-financial interests to disclose.
Figures



Similar articles
-
The emerging role of anti-PD-1 antibody-based regimens in the treatment of extranodal NK/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis.J Cancer Res Clin Oncol. 2023 May;149(5):2017-2027. doi: 10.1007/s00432-022-04147-2. Epub 2022 Jul 9. J Cancer Res Clin Oncol. 2023. PMID: 35809114 Free PMC article.
-
Serum cytokine pattern for the early identification of hemophagocytic lymphohistiocytosis in diffuse large B-cell lymphoma.Cytokine. 2025 Oct;194:157000. doi: 10.1016/j.cyto.2025.157000. Epub 2025 Jul 24. Cytokine. 2025. PMID: 40712436
-
Modified DEP regimen as induction therapy for lymphoma-associated hemophagocytic lymphohistiocytosis: a prospective, multicenter study.J Cancer Res Clin Oncol. 2023 Jul;149(7):3033-3041. doi: 10.1007/s00432-022-04157-0. Epub 2022 Jul 19. J Cancer Res Clin Oncol. 2023. PMID: 35852619 Free PMC article.
-
Positron emission tomography-adapted therapy for first-line treatment in individuals with Hodgkin lymphoma.Cochrane Database Syst Rev. 2015 Jan 9;1(1):CD010533. doi: 10.1002/14651858.CD010533.pub2. Cochrane Database Syst Rev. 2015. Update in: Cochrane Database Syst Rev. 2025 Mar 26;3:CD010533. doi: 10.1002/14651858.CD010533.pub3. PMID: 25572491 Free PMC article. Updated.
-
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4. Cochrane Database Syst Rev. 2021. Update in: Cochrane Database Syst Rev. 2022 May 23;5:CD011535. doi: 10.1002/14651858.CD011535.pub5. PMID: 33871055 Free PMC article. Updated.
Cited by
-
Hemophagocytic Lymphohistiocytosis and the Liver Masquerade.Cureus. 2025 Jul 1;17(7):e87133. doi: 10.7759/cureus.87133. eCollection 2025 Jul. Cureus. 2025. PMID: 40747175 Free PMC article.
-
Clinicopathological characteristics, prognostic factors, and outcomes of elderly patients with lymphoma-associated hemophagocytic lymphohistiocytosis: A multicenter analysis.Cancer Med. 2024 Aug;13(16):e70178. doi: 10.1002/cam4.70178. Cancer Med. 2024. PMID: 39219182 Free PMC article.
-
Approaching hemophagocytic lymphohistiocytosis.Front Immunol. 2023 Jun 22;14:1210041. doi: 10.3389/fimmu.2023.1210041. eCollection 2023. Front Immunol. 2023. PMID: 37426667 Free PMC article. Review.
-
[Expression and diagnostic value of lymphocyte subsets and activation status in non-Hodgkin's lymphoma-associated hemophagocytic lymphohistiocytosis].Zhonghua Xue Ye Xue Za Zhi. 2024 Aug 14;45(8):748-754. doi: 10.3760/cma.j.cn121090-20240409-00129. Zhonghua Xue Ye Xue Za Zhi. 2024. PMID: 39307721 Free PMC article. Chinese.
-
DEP regimen for the treatment of hemophagocytic lymphohistiocytosis: a review of published experience.Front Pharmacol. 2025 Jun 11;16:1599873. doi: 10.3389/fphar.2025.1599873. eCollection 2025. Front Pharmacol. 2025. PMID: 40567361 Free PMC article. Review.
References
-
- Al-Samkari H, Berliner N (2018) Hemophagocytic lymphohistiocytosis. Annu Rev Pathol 13:27–49. 10.1146/annurev-pathol-020117-043625 - PubMed
-
- Bains A, Mamone L, Aneja A, Bromberg M (2017) Lymphoid malignancy-associated hemophagocytic lymphohistiocytosis: search for the hidden source. Ann Diagn Pathol 28:37–42. 10.1016/j.anndiagpath.2017.02.009 - PubMed
-
- Chinese Physicians Association, Haematology Section, Chinese Medical Association, Haematology Group, Chinese Expert Alliance for Hemophagocytic Syndrome (2022) Chinese guidelines for the diagnosis and treatment of hemophagocytic syndrome (2022 edition). Chin Med J 102(20):1492–1499. 10.3760/cma.j.cn112137-20220310-00488
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous